Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.

@article{Overkamp2002AcuteEO,
  title={Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.},
  author={D. Overkamp and A. Volk and E. Maerker and P. Heide and H. Wahl and K. Rett and H. H{\"a}ring},
  journal={Diabetes care},
  year={2002},
  volume={25 11},
  pages={
          2065-73
        }
}
OBJECTIVE This study addressed whether acute infusion of glimepiride influences glucose metabolism independent of its effect on insulin secretion. RESEARCH DESIGN AND METHODS Ten healthy, glucose-tolerant but insulin-resistant probands were subjected to a placebo-controlled, double-blind, cross-over study. Each individual received infusions of either 0.15 mol/l saline or glimepiride in randomized order on two separate occasions. A three-step hyperinsulinemic (0.5, 1.0, and 1.5 mU. kg(-1). min… Expand
Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus.
TLDR
In this study, glimepiride achieved desirable glycemic control in patients with recent-onset type 2 DM through improvement in insulin secretion and sensitivity. Expand
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
TLDR
Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity. Expand
Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.
TLDR
Glimepiride and metformin are effective individually in achieving a glycemic goal with a less daily insulin dose, weight gain, and hypoglycemic episodes in comparison to insulin monotherapy in subjects with type 2 diabetes mellitus with further marked reduction in these parameters when used concurrently. Expand
[Future targets in the treatment of type 2 diabetes].
TLDR
New agonists of the peroxisome proliferator activator receptor gamma (PPAR gamma) as well as combined PPAR alpha/gamma agonists are developed at present, but the direct modulation of insulin signal transduction is still limited to experimental studies. Expand
Glimepiride: evidence-based facts, trends, and observations
TLDR
Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin and is effective in reducing fasting plasma glucose, post-prandial glucose, and glycosylated hemoglobin levels and is a useful, cost-effective treatment option for managing type 2 diabetes mellitus. Expand
Zukünftige Angriffspunkte für die Therapie des Typ-2-Diabetes
TLDR
New agonists of the peroxisome proliferator activator receptor γ (PPARγ) as well as combined PPAR α/γ agonists are developed at present, but the direct modulation of insulin signal transduction is still limited to experimental studies. Expand
The role of glimepiride in the treatment of type 2 diabetes mellitus
TLDR
Therapy with glimepiride improves the relative insulin secretory deficit found in type 2 diabetes mellitus, has antihyperglycemic efficacy equal to other secretagogues with reduced potential for hypoglycemia and may have additional actions contributing to glycemic control in T2DM. Expand
The role of glimepiride in combination with metformin in modern practice of using antihyperglycemic therapy for type 2 diabetes mellitus
The article describes the role of sulfonylurea medications in modern recommendations concerning the treatment of patients with diabetes mellitus type 2. We showed the characteristics of mechanism ofExpand
Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
TLDR
Based on the evidence to date, glimepiride is an effective and well-tolerated once-daily antidiabetic drug and provides an important treatment option for the management of type 2 diabetes. Expand
Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide.
TLDR
It is suggested that glimepiride improves insulin resistance in hyperinsulinemic patients treated with glibenclamide and is favored especially for overweight, insulin-resistant patients inadequately controlled by glibanclamide. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 39 REFERENCES
A stimulatory effect of tolbutamide on the insulin-mediated glucose uptake in subjects with impaired glucose tolerance (IGT).
TLDR
It seems to be that a successful short-term sulfonylurea therapy on glucose utilization is associated with some alterations on the receptor and/or post-receptor level, indicating a higher insulin sensitivity. Expand
Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo.
TLDR
Evidence is provided for an extrapancreatic effect of glibenclamide at low insulin concentrations during euglycemic clamping in patients with insulin-dependent diabetes mellitus, however, this effect was not reflected clinically in either an increased rate of hypoglycemic reactions or decreased insulin needs during the short term period of treatment. Expand
Different Effects of Glyburide and Glipizide on Insulin Secretion and Hepatic Glucose Production in Normal and NIDDM Subjects
TLDR
The results indicate that the acute administration of GB and GZ to NIDDM subjects has quantitatively different results on hepatic glucose production and acute plasma insulin response to hyperglycemia, challenging the concept that sulfonylurea agents, when given acutely, potentiate glucose-stimulated insulin secretion. Expand
Effect of Sulfonylurea Treatment on In Vivo Insulin Secretion and Action in Patients With Non-insulin-dependent Diabetes Mellitus
TLDR
Chronic therapy with glipizide, a new sulfonylurea agent, led to increased in vivo insulin secretion and insulin action, and it is suggested that this effect contributes to the therapeutic efficacy of these drugs. Expand
Sulfonylureas enhance in vivo the effectiveness of insulin in type 1 (insulin dependent) diabetes mellitus.
TLDR
Insulin sensitivity was studied in 9 type 1 diabetics with no residual insulin secretory activity and data strongly suggest that the two sulfonylureas employed enhance in vivo the peripheral sensitivity to insulin. Expand
Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects.
TLDR
The data indicate that sulfonylurea treatment did not improve the diminished insulin sensitivity of peripheral glucose clearance in type 1-diabetic subjects; insulin action on hepatic glucose production and lipolysis was unimpaired in diabetics and remained uninfluenced by glibornuride. Expand
Comparative effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin concentrations in the fasting and postprandial state in normal man.
TLDR
In the fasting state, glimepiride and glibenclamide had similar effects on the changes in blood glucose levels after i.v. administration, suggesting either that glimpiride induces insulin secretion through a pathway which is different from that of glibanclamide or that glimePiride facilitates insulin action through extrapancreatic effects. Expand
[Effect of glipizide on glycemic control and peripheral insulin sensitivity in type 1 diabetics].
TLDR
The results suggest that in type 1 diabetic patients the addition of Glipizide to insulin therapy does not alter glycaemic control and peripheral insulin sensitivity. Expand
The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects
TLDR
Glyburide therapy increases endogenous insulin secretion, increases adipocyte insulin binding after 18, but not 3, mo of therapy, enhances peripheral insulin action by acting primarily at a post-receptor site, and reduces basal hepatic glucose output. Expand
Longitudinal evaluation of the effects of sulfonylurea therapy in subjects with type II diabetes mellitus.
TLDR
The increase in post-receptor function and the reduction of basal hepatic glucose output appear to be the crucial determinants of the clinical response to the sulfonylurea; the response pattern to sulfonyLurea compounds can vary as a function of the duration of treatment. Expand
...
1
2
3
4
...